Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Method Developed to Detect AFP and GP73 Simultaneously

By LabMedica International staff writers
Posted on 05 Jun 2018
Liver cancer is the second leading cause of cancer death in males and the sixth in females worldwide. An estimated 782,500 new liver cancer cases and 745,500 deaths occurred worldwide during 2012.

Alpha-fetoprotein (AFP) is a biomarker that is commonly used in the clinic for Hepatocellular Carcinoma (HCC) diagnosis and to predict HCC progression especially in chronic hepatitis B (HBV) infected patients. Golgi protein 73 (GP73) is a biomarker for advanced liver diseases and the increase in GP73 levels is correlated with various liver diseases.

Scientists at Capital Medical University, Beijing, PR China) used anti-human AFP and GP73 monoclonal antibodies to develop a sandwich immunity reaction using xMAP technology for the simultaneous detection of plasma AFP and GP73. The assay evaluated the sensitivity, cross reactivity, range of detection, precision, recovery and linearity dilution effect. The assay utilized plasma samples and compared its performance with commercially available Enzyme Linked Immunosorbent Assay (ELISA) kits. The team used the Luminex-200 analyzer and the iMark microplate reader.

The scientists analyzed 80 clinical plasma samples using the Luminex multiplex assay system and commercially available ELISA kits. The correlation coefficient of AFP and GP73 were 0.997 and 0.959 respectively. The results showed that the AFP levels from HCC patient samples were significantly higher than from patient samples with liver cirrhosis and healthy controls. However, AFP levels in patients with liver cirrhosis were not significantly different from that of healthy controls. The GP73 levels of samples from HCC and liver cirrhosis patients were significantly higher than healthy controls; however, the GP73 levels from patients with HCC and liver cirrhosis were not significantly different.

The authors concluded that they have established a new method to detect AFP and GP73 levels in plasma samples simultaneously using the Luminex xMAP technology. The method demonstrated a sensitive, effective, and accurate method and the assay could be used clinically for routine detection and monitoring of patients with HBV related diseases. The study was published in the July 2018 issue of the journal Clinica Chimica Acta.

Related Links:
Capital Medical University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.